Showing results (621-630 of 667) with videos related to
Sort By:
Pageof 67
British Journal of Cancer|May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patientsAnne-Marie O'Farrell, James M Foran, Walter Fiedler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.The American Journal of Surgical Pathology|January 29, 2008
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumorsInigo Espinosa, Cheng-Han Lee, Mi Kyung Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.Blood|February 7, 2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemiaMarc M Loriaux, Ross L Levine, Jeffrey W Tyner, et al.Pageof 67